Search
Close this search box.

N-mAb

The goal of the N-mAb initiative is to convene thought leaders to establish shared vocabulary and understanding by which the industry can think about integrated/continuous processes with respect to regulatory considerations.
Categories
Proteins/ Antibodies
Drug substance
Assays
Process control
Project status
100% Completed

Solution

The A-mAb case study (2009) created value in the biopharmaceutical industry by bringing industry and regulatory stakeholders together to develop shared expectations and vocabulary for quality by design. Participation included key thought leaders in industry and from relevant federal agencies. NIIMBL is committed to supporting and accelerating the adoption of integrated and continuous processes for manufacturing biopharmaceuticals.

The goal of the N-mAb initiative is to convene thought leaders to establish shared vocabulary and understanding by which the industry can think about integrated/continuous processes with respect to regulatory considerations. Specifically the key deliverable of this project is a published control strategy framework for a hypothetical integrated/continuous monoclonal antibody manufacturing process.

View and download N-mAb at https://niimbl.force.com/s/n-mab.

Outcomes and Impacts

Case study that supports teaching and learning for both industry and regulators around adoption of advanced manufacturing process technologies for mAbs

Updates, Related Publications, and Deliverables

  • Login to the NIIMBL member portal for access to project updates, related publications, and deliverables. 

Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.

Participating Organizations

Federal Stakeholder:  National Institute of Standards and Technology

Federal Stakeholder: National Institute of Standards and Technology

NIIMBL

NIIMBL

Join Our Mailing List

MailChimp NIIMBL Mailing List Signup
Organization Type
How did you first hear about NIIMBL?